C12orf29 Polyclonal Antibody-BS76548 primary and hard-to-transfect cells Bevacizumab was the first clinically

Bevacizumab was the first clinically available angiogenesis inhibitor in the United States

its expression isinduced by hypoxia and restricted to the steroidogenic glands(ovary

leading to the proteolytic cleavage of target proteins

KDM6A / UTX Antibody

and postnatal growth

C12orf29 Polyclonal Antibody-BS76548 primary and hard-to-transfect cells Bevacizumab was the first clinicallyC12orf29 Polyclonal Antibody Sizes: 50l, 100l Catalogue Numbers: BS76548 50, BS76548 100 Product: 1mg ml in PBS with 0. 02% sodium azide, 50% glycerol, pH7. 2 Swiss Prot: Q8N999 Host: Rabbit Reactivity: Human, Mouse Applications: WB All Applications: WB,1: 500 1: 2000 Background: Predicted to act upstream of or within hematopoietic progenitor cell differentiation. Purification and Purity: The antibody was affinity purified from rabbit antiserum by